Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers

BACKGROUND: The human epidermal growth factor receptor (EGFR) is an important target for cancer treatment. Currently, only the EGFR antibodies cetuximab and panitumumab are approved for the treatment of patients with colorectal cancer. However, a major clinical challenge is a short-term response owi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Cancer
Главные авторы: Khelwatty, Said A, Essapen, Sharadah, Seddon, Alan M, Fan, Zhen, Modjtahedi, Helmout
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2015
Предметы:
Translational Therapeutics
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4651123/
https://ncbi.nlm.nih.gov/pubmed/26372697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.319
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы